May 14 (Reuters) - John Lechleiter, the longtime chief executive of Eli Lilly and Co, is recovering from successful surgery to repair a dilated aorta, the U.S. drugmaker said on Tuesday.

May 14 (Reuters) - John Lechleiter, the longtime chief executive of Eli Lilly and Co, is recovering from successful surgery to repair a dilated aorta, the U.S. drugmaker said on Tuesday.

Looking at the universe of stocks we cover at Dividend Channel, on 5/14/13, Eli Lilly & Co. (NYSE: LLY) will trade ex-dividend, for its quarterly dividend of $0.49, payable on 6/10/13. As a percentage of LLY's recent stock price of $54.25, t

May 10 (Reuters) - Eli Lilly and Co said it will enddevelopment of an experimental cancer drug after it failed in alate-stage trial to delay a worsening of symptoms in patientswith lymphoma.

May 10 (Reuters) - Eli Lilly and Co said it will end development of an experimental cancer drug after it failed in a late-stage trial to delay a worsening of symptoms in patients with lymphoma.

May 10 (Reuters) - Eli Lilly and Co said it will end development of an experimental cancer drug after it failed in a late-stage trial to delay a worsening of symptoms in patients with lymphoma.

May 10 (Reuters) - Eli Lilly and Co said it will end development of an experimental cancer drug after it failed in a late-stage trial to delay a worsening of symptoms in patients with lymphoma.

May 10 (Reuters) - Eli Lilly and Co said it will stop developing its experimental cancer drug after a late-stage trial failed to show a statistically significant increase in patients' disease-free survival.

May 10 (Reuters) - Eli Lilly and Co said it willstop developing its experimental cancer drug after a late-stagetrial failed to show a statistically significant increase inpatients' disease-free...

May 10 (Reuters) - Eli Lilly and Co said it will stop developing its experimental cancer drug after a late-stage trial failed to show a statistically significant increase in patients' disease-free survival.

Eli Lilly and Company (NYSE: LLY) announced today Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL).

Drug maker Eli Lilly said Chairman and Chief Executive John C. Lechleiter will hand over his duties to others while he undergoes surgery to repair an enlarged artery and recovers for a few months.

(Reuters) - Eli Lilly & Co's longtime Chief Executive John Lechleiter will undergo surgery next Monday for a dilated aorta, but is expected to make a full recovery from the potentially dangerous condition and return to work this summer, the drugmaker

May 6 (Reuters) - Eli Lilly & Co's longtime Chief Executive John Lechleiter will undergo surgery next Monday for a dilated aorta, but is expected to make a full recovery from the potentially dangerous condition and return to work this summer, the dru

May 6 (Reuters) - Eli Lilly & Co's longtime Chief Executive John Lechleiter will undergo surgery next Monday for a dilated aorta, but is expected to make a full recovery from the potentially dangerous condition and return to work this summer, the dru

(Reuters) - Drug maker Eli Lilly and Co said Chief Executive John Lechleiter will undergo a surgery on May 13 to treat a dilated aorta but is expected to recover and return to work by this summer.

May 6 (Reuters) - Drug maker Eli Lilly and Co said Chief Executive John Lechleiter will undergo a surgery on May 13 to treat a dilated aorta but is expected to recover and return to work by this summer.

In today's post, I am using charts of Eli Lilly to give you an idea of how I use Elliott Wave analysis in real life trading. The analysis follows a systematic look at the charts to determine if an acceptable wave count can be found, and then I d

By Valuentum:Dividend growth investing is lots of fun, especially if you have a systematic methodology to determining which companies' dividends are safe and which ones' aren't. That is why we created a forward-looking assessment of dividend safety i

April 24 (Reuters) - Eli Lilly and Co : * Says weakening yen could crimp company sales in japan by $300 million to $400

Eli Lilly's first-quarter net profit rose 53%, thanks in part to a gain from transferring some commercial rights, while margins improved despite flat revenue.

April 24 (Reuters) - Eli Lilly and Co on Wednesday reported higher-than-expected first-quarter earnings, helped by favorable taxes and higher sales of its treatments for diabetes, depression and lung cancer.

April 24 (Reuters) - Eli Lilly and Co on Wednesday reported higher-than-expected first-quarter earnings, helped by favorable taxes and higher sales of its treatments for diabetes, depression and lung cancer.

April 24 (Reuters) - Eli Lilly and Co on Wednesday reported higher-than-expected first-quarter earnings, helped by sales of its treatments for diabetes, depression and lung cancer.

April 24 (Reuters) - Eli Lilly and Co on Wednesday reported higher-than-expected first-quarter earnings, helped by sales of its treatments for diabetes, depression and lung cancer.

By WhisperNumber: Eli Lilly and Company (LLY) is expected to report fiscal first quarter earnings on Wednesday, April 24th. The whisper number is $1.01, four cents behind the analysts' estimate. LLY has a 73% positive surprise history (having topped

Eli Lilly (NYSE: LLY), which last week announced a deal to buy two imaging agents from Siemens (NYSE: SI) that could help aid the fight against Alzheimer's, is scheduled to report its first-quarter 2013 results Wednesday, April 24, before the markets

By Peter Geschek:Eli Lilly (LLY) has suffered a number of setbacks lately.Its profit fell 6 percent last year as it lost its U.S. patent protection for top-selling schizophrenia drug Zyprexa. At the end of 2013 the Lilly antidepressant Cymbalta will

Can Eli Lilly crack the Alzheimer's code?

By EP Vantage:Eli Lilly (LLY) has made it five out of five for positive pivotal data for its brightest pipeline hope, dulaglutide, setting the stage for an end of year filing for the GLP-1 agonist and the company's planned fightback against the domin

Eli Lilly and Company (NYSE: LLY)today announced it has acquired two investigational positron emissiontomography (PET) tracers from Siemens Medical Solutions USA, Inc. The tracersare intended to image tau (or neurofibrillary) tangles in the brain, on

CHICAGO, April 17 (Reuters) - In a move to shore up its lead in Alzheimer's diagnostics, Eli Lilly and Co on Wednesday said it will acquire two imaging agents from Siemens designed to light up brain deposits of tau, an Alzheimer's protein linked with

CHICAGO, April 17 (Reuters) - In a move to shore up its lead in Alzheimer's diagnostics, Eli Lilly and Co on Wednesday said it will acquire two imaging agents from Siemens designed to light up brain deposits of tau, an Alzheimer's protein linked with

CHICAGO, April 17 (Reuters) - In a move to shore up its lead in Alzheimer's diagnostics, Eli Lilly and Co on Wednesday said it will acquire two imaging agents from Siemens designed to light up brain deposits of tau, an Alzheimer's protein linked with

CHICAGO, April 17 (Reuters) - In a move to shore up its lead in Alzheimer's diagnostics, Eli Lilly and Co on Wednesday said it will acquire two imaging agents from Siemens designed to light up brain...

Eli Lilly is taking its Alzheimer's disease research in a new direction, a move that deepens the drug maker's efforts to find tests and treatments for the memory-robbing disorder despite a costly setback last year.

April 16 (Reuters) - Eli Lilly and Co said two additional late-stage studies testing its experimental diabetes drug dulaglutide met the main goal of reducing hemoglobin A1c levels, a measure of blood sugar.

April 16 (Reuters) - Eli Lilly and Co said twoadditional late-stage studies testing its experimental diabetesdrug dulaglutide met the main goal of reducing hemoglobin A1clevels, a measure of blood...

Eli Lilly hits a very rough patch.

The end of patent protection will reportedly mean 1,000 salespeople lose their jobs.

April 11 (Reuters) - Drugmaker Eli Lilly and Co plans to lay off about 1,000 domestic sales representatives, or 30 percent of its U.S. sales force, as it faces new generic competition for its top drugs, a person familiar with the matter said on Frida

April 11 (Reuters) - Drugmaker Eli Lilly and Co plans to lay off about 1,000 domestic sales representatives, or 30 percent of its U.S. sales force, as it faces new generic competition for its top drugs, a person familiar with the matter said on Frida

April 11 (Reuters) - U.S. drugmaker Eli Lilly and Co plans to layoff about 1,000 domestic sales representatives to reduce costs, as it faces daunting generic competition, the Wall Street Journal reported, citing a person familiar with the matter.

April 11 (Reuters) - U.S. drugmaker Eli Lilly and Co plans to layoff about 1,000 domestic sales representatives to reduce costs, as it faces daunting generic competition, the Wall Street Journal reported, citing a person familiar with the matter.

Eli Lilly plans to lay off about 1,000 sales representatives in the U.S., in a major restructuring that aims to cut the drug maker's costs in preparation for generic competition that will face two of its biggest-selling products. The layoffs will aff

LOS ANGELES (MarketWatch) -- Eli Lilly & Co.said late Thursday it will restructure its sales force and cut personnel, but the drug maker wouldn't confirm a report that 1,000 layoffs are planned. The Wall Street Journal said 1,000 sales people at Indi

Teva Pharmaceutical Industries (NYSE: TEVA) today announced theappointment of Ichiro Kikushige as Chief Executive Officer (CEO) of TevaSeiyaku, Japan, effective on May 15, 2013. Mr. Kikushige most recentlywas Senior Director of Sales for Eli Lilly Ja

Eli Lilly and Company (NYSE: LLY)today announced that it is working closely with the city on a proposal toinvest an additional $180 million in the company's Indianapolis-based insulinmanufacturing operations.